X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nefegan (budesonide) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. it is approved for the treatment of primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefegan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Nefecon (budesonide) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. it is approved for the treatment of primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Calliditas Therapeutics AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Velsipity (etrasimod), an FDA approved oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator. Its NDA is also been accepted by Macau Special Administrative Region for adults with moderately to severely active ulcerative colitis.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Product Name: Velsipity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kezar Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Through the termination, Everest will continue to develop its products utilizing the mRNA-based vaccine and will own full intellectual property rights and full global rights of those products.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Providence Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination February 18, 2024
Details:
Nefecon (budesonide) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. it is approved for the treatment of primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Zetomipzomib
Therapeutic Area: Nephrology Product Name: KZR-616
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2023
Details:
Velsipity (etrasimod) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. It is approved for the treatment of patients with moderately to severely active ulcerative colitis.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Product Name: Velsipity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It is being evaluated for the treatment of primary IgA nephropathy in adult patients.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. It is being investigated for primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Product Name: Nefecon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Calliditas Therapeutics AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
